A prospective study examining PROs and other geriatric outcomes in older adults with prostate cancer undergoing chemotherapy.

9555 Background: Treatment of metastatic castration-resistant prostate cancer (mCRPC) with chemotherapy improves disease control and survival in older men (age 65+) based on large clinical trials. ...